The COVID-19 pandemic is currently a worldwide threat and concern, not only because of COVID-19 itself but its sequelae. The aim of this study was to evaluate whether a relation between COVID-19, Long COVID, and the prevalence of mental health disorders exist. A total of 203 people from Tabasco were included in this study, answering a survey integrated by three dominions: General and epidemiological data, the DASS-21 test (to determine the presence of signs or symptoms suggestive of depression, anxiety, and/or stress) and an exploratory questionnaire about Long COVID syndrome. A descriptive and inferential statistical analysis was made via Microsoft Excel and Graphpad Prism software, evaluating differences through the Mann–Whitney U test and considering p < 0.05 as statistically significant. Of the 203 people surveyed, 96 (47.29%) had had COVID-19 and 107 (52.71%) had not; from the ones that had COVID-19, 29 (30.21%) presented mental health disorders and 88 (91.66%) presented at least one symptom or sign of Long COVID syndrome; meanwhile, 31 (32.29%) presented 10 or more symptoms or signs. From the comparison between the population with previous mental health disorders and COVID-19 and those without background disorders or COVID-19, the results were the following: 27.58% vs. 16.82% presented severe depression, 48.27% vs. 17.75% presented severe anxiety, and 27.58% vs. 20.56% presented severe stress. A high prevalence of mental health effects was observed in patients without COVID-19 and increased in the population with Long COVID syndrome and previous mental health disorders.
Introduction: Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19. Methodology: We analysed the data obtained by an observational cohort of patients with SARS-CoV-2 pneumonia treated with ruxolitinib in 22 hospitals of Mexico. The applied dose was determined based on physician’s criteria. The benefit of ruxolitinib was evaluated using the 8-points ordinal scale developed by the NIH in the ACTT1 trial. Duration of hospital stay, changes in pro-inflammatory laboratory values, mortality, and toxicity were also measured. Results: A total of 287 patients were reported at 22 sites in Mexico from March to June 2020; 80.8% received ruxolitinib 5 mg BID and 19.16% received ruxolitinib 10 mg BID plus standard of care. At beginning of treatment, 223 patients were on oxygen support and 59 on invasive ventilation. The percentage of patients on invasive ventilation was 53% in the 10 mg and 13% in the 5 mg cohort. A statistically significant improvement measured as a reduction by 2 points on the 8-point ordinal scale was described (baseline 5.39 ± 0.93, final 3.67± 2.98, p = 0.0001). There were 74 deaths. Serious adverse events were presented in 6.9% of the patients. Conclusions: Ruxolitinib appears to be safe in COVID-19 patients, with clinical benefits observed in terms of decrease in the 8-point ordinal scale and pro-inflammatory state. Further studies must be done to ensure efficacy against mortality.
<p><strong>Objetivo: </strong>describir las características epidemiológicas y clínicas al ingreso de pacientes hospitalizados con diagnóstico de covid-19, en un hospital general en Tabasco, México. <strong>Métodos:</strong> estudio transversal analítico realizado en el Centro Médico del Instituto de Seguridad Social del Estado de Tabasco (isset) “Dr. Julián A. Manzur Ocaña”, en Tabasco, México; del 1 de junio al 31 de julio del 2020, en los módulos de atención de pacientes con diagnóstico sospechosos o confirmados con sars-CoV-2. <strong>Resultados: </strong>se obtuvo una muestra de 140 casos positivos a sars-CoV-2, 51.42% pertenecía al sexo masculino. Los principales síntomas fueron disnea, tos seca y fiebre. Se observó un mayor incremento de factores inflamatorios y trombóticos en hombres. El tratamiento consistió en antipiréticos, antiagregantes plaquetarios, antimicrobianos y esteroides. El requerimiento de oxígeno suplementario fue similar en mujeres y hombres, sin embargo, la saturación de oxígeno fue mayor en mujeres. <strong>Conclusión:</strong> la frecuencia de 140 casos positivos a covid-19, con sintomatología característica de la enfermedad. Con incremento de parámetros inflamatorios y trombóticos. El tratamiento fue sintomático más oxígeno suplementario.</p>
<p><strong>Objetivo: </strong>describir las características epidemiológicas y clínicas al ingreso de pacientes hospitalizados con diagnóstico de covid-19, en un hospital general en Tabasco, México. <strong>Métodos:</strong> estudio transversal analítico realizado en el Centro Médico del Instituto de Seguridad Social del Estado de Tabasco (isset) “Dr. Julián A. Manzur Ocaña”, en Tabasco, México; del 1 de junio al 31 de julio del 2020, en los módulos de atención de pacientes con diagnóstico sospechosos o confirmados con sars-CoV-2. <strong>Resultados: </strong>se obtuvo una muestra de 140 casos positivos a sars-CoV-2, 51.42% pertenecía al sexo masculino. Los principales síntomas fueron disnea, tos seca y fiebre. Se observó un mayor incremento de factores inflamatorios y trombóticos en hombres. El tratamiento consistió en antipiréticos, antiagregantes plaquetarios, antimicrobianos y esteroides. El requerimiento de oxígeno suplementario fue similar en mujeres y hombres, sin embargo, la saturación de oxígeno fue mayor en mujeres. <strong>Conclusión:</strong> la frecuencia de 140 casos positivos a covid-19, con sintomatología característica de la enfermedad. Con incremento de parámetros inflamatorios y trombóticos. El tratamiento fue sintomático más oxígeno suplementario.</p>
Introduction: Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19 cases. Methods: We analysed the data obtained for an observational cohort of patients with SARS-CoV-2 pneumonia treated with ruxolitinib in 22 hospitals of Mexico. The dose used was determined based on physician’s criteria. The benefit of ruxolitinib was evaluated using the 8-points ordinal scale developed by the NIH in the ACTT1 trial. Duration of hospital stay, changes in pro-inflammatory laboratory values, mortality, and toxicity were also measured. Results: A total of 287 patients administered ruxolitinib were reported at 22 sites in Mexico from March to June 2020; 80.8% received 5 mg BID and 19.16% received 10 mg BID ruxolitinib. At the beginning of treatment, 223 patients were on oxygen support, 59 on invasive ventilation. The percentage of patients on invasive ventilation was 53% in the 10 mg and 13% in the 5 mg cohort. There was a statistically significant improvement measured as a reduction by 2 points (initial 5.39 ± 0.93, final 3.67± 2.98, P value = 0.0001) on the 8-point ordinal scale. There were a total of 74 deaths. Serious adverse events were presented in 6.9% of the patients. Conclusion: Ruxolitinib appears to be safe in COVID-19 patients, with clinical benefits observed in terms of decrease in the 8-point ordinal scale and pro-inflammatory state. Further studies must be done to ensure efficacy against mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.